Major R&D Pipeline: 3ADCs

Japan: New Product Approval Oncolytic virus G47A* (product name: DELYTACT ® ) was approved in June 2021, which was co-developed with Dr. Todo of the Institute of Medical Science, The University of Tokyo The first oncolytic virus in the world to target malignant glioma Generic name: teserpaturev Indication: malignant glioma Grade III and grade IV among glioma which originates in glial cells in brain tissue ➤ Estimated number of new patients in Japan: around 2,800 patients annually Overview of the approval Daiichi-Sankyo The approval is primarily based on the results of Japan Ph2 study (investigator initiated study) in patients. with residual or recurrent glioblastoma conducted by Dr. Todo of the Institute of Medical Science, The University of Tokyo ➤ Received conditional and time-limited approval which requires verification of clinical benefit and safety within 7 years for all patients treated with DELYTACT ® *G47A The third generation oncolytic herpes simplex virus type 1 created by Dr. Todo and his colleagues at the Institute of Medical Science, The University of Tokyo. DELYTACT® has triple mutation within the viral genome and is designed to replicate selectively in cancer cells. 13

View entire presentation